Lupin Ltd — Capital/Financing Update 2018

Oct 9, 2018

Press Release Press Release

==> picture [45 x 53] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin launches generic Clobetasol Propionate Ointment USP 0.05% in the US

Mumbai, Baltimore, October 09, 2018 : Pharma major Lupin announced the launch of Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Clobetasol Propionate Ointment USP 0.05% had annual sales of approximately USD 93.4 million in the US (IQVIA MAT June 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8[th] largest generics pharmaceutical company both in terms of market capitalization (30[th] June 2018, Bloomberg) and revenues (31[st] March 2018, Bloomberg LTM) globally. The Company is the 4[th] largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3[rd] largest Indian pharmaceutical company by global revenues (31[st] March 2018, Bloomberg LTM); 6[th] largest generic pharmaceutical player in Japan and 5[th] largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31[st] March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3[rd] Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Arvind Bothra Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66402137

*Safe Harbor Statement Temovate is a registered trademark of Fougera Pharmaceuticals Inc.